CD24+/CD38- as new prognostic marker for non-small cell lung

Background Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. Methods In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. Results We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. Conclusions We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.

Frontiers Lung Cancer Stem Cell Markers as Therapeutic Targets

JCM, Free Full-Text

Emerging phagocytosis checkpoints in cancer immunotherapy

PDF) Rodent abundance, stone bund density and its effects on crop

PDF) Sylvie Crogiez-Pétrequin (dir.), Dieu (x) et hommes. Histoire

Cancers, Free Full-Text

Emerging phagocytosis checkpoints in cancer immunotherapy

PDF) Décalages, failles et explosions – Zabriskie Point de

B cells in tumor metastasis: friend or foe?

PDF) Sleep apnoea detection in children using PPG envelope-based

CD24+/CD38- as new prognostic marker for non-small cell lung

JCM, Free Full-Text

Revised International Staging System (R-ISS) stage-dependent

B cells and tertiary lymphoid structures as determinants of tumour